Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

被引：0
|
作者：
Wiendl, H. [1 ]
De Stefano, N. [2 ]
Barkhof, F. [3 ]
Montalban, X. [4 ]
Achiron, A. [5 ]
Derfuss, T. [6 ]
Chan, A. [7 ]
Hodgkinson, S. [8 ]
Prat, A. [9 ]
Leocani, L. [10 ]
Schmierer, K. [11 ]
Sellebjerg, F. [12 ]
Vermersch, P. [13 ]
Jin, H. [14 ]
Jaervinen, E. [14 ]
Chudecka, A. [15 ]
Gardner, L. [16 ]
机构：
[1] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany
[2] Univ Siena, Dept Med Surg & Neurosci, Siena, Italy
[3] Vrije Univ Amsterdam, Dept Radiol, Med Ctr, Amsterdam, Netherlands
[4] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain
[5] Sheba Acad Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel
[6] Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[7] Bern Univ, Univ Hosp Bern, Dept Neurol, Inselspital, Bern, Switzerland
[8] Univ New South Wales Med, Ingham Inst Appl Med Res, Sydney, Australia
[9] Univ Montreal, Dept Neurosci, Montreal, PQ, Canada
[10] Univ Vita Salute San Raffaele, Expt Neurophysiol Unit, Milan, Italy
[11] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, Ctr Neurosci Surg & Trauma, London, England
[12] Rigshosp, Dept Neurol, Danish MS Ctr, Copenhagen Univ Hosp, Glostrup, Denmark
[13] Univ Lille, INSERM, U1172, LilNCog,CHU Lille,FHU Precise, Lille, France
[14] Healthcare Business Merck KGaA, Darmstadt, Germany
[15] Cytel Inc, Geneva, Switzerland
[16] EMD Serono Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P008
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [31] Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
    Brochet, Bruno
    Solari, Alessandra
    Lechner-Scott, Jeannette
    Piehl, Fredrik
    Langdon, Dawn
    Hupperts, Raymond
    Selmaj, Krzysztof
    Patti, Francesco
    Brieva, Luis
    Maida, Eva Maria
    Alexandri, Nektaria
    Smyk, Andrzej
    Nolting, Axel
    Keller, Birgit
    Montalban, Xavier
    Kubala Havrdova, Eva
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (14) : 1808 - 1818
  • [32] Time to Qualifying Relapse by Previous Disease Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets over 2 Years in the CLARIFY-MS Study
    Patti, Francesco
    Brochet, Bruno
    Havrdova, Eva Kubala
    Solari, Alessandra
    Hupperts, R. M. M.
    Langdon, Dawn
    Lechner-Scott, Jeannette
    Piehl, Fredrik
    Selmaj, Krzysztof
    Smyk, Andrzej
    Lehn, Annette
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 747 - 748
  • [33] The effect of natalizumab on brain atrophy in patients with relapsing multiple sclerosis: 2-year results from the AFFIRM study
    Fisher, E
    O'Connor, R
    Havrdova, E
    Hutchinson, M
    Kappos, L
    Miller, D
    Phillips, JT
    Polman, C
    Lublin, R
    Giovannoni, G
    Wajgt, A
    Rudick, R
    Lynn, F
    Toal, M
    Panzara, M
    Sandrock, A
    JOURNAL OF NEUROLOGY, 2005, 252 : 149 - 149
  • [34] 2-Year follow-up data of multiple sclerosis patients treated with cladribine: a single center, a real world study
    Uzuner, Gulnur Tekgol
    Celikeloglu, Elifnur
    Uzuner, Nevzat
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1114 - 1115
  • [35] Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study
    Stelmasiak, Z.
    Solski, J.
    Nowicki, J.
    Jakubowska, B.
    Ryba, M.
    Grieb, P.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (06) : 767 - 770
  • [36] The gut-brain-axis one year after treatment with cladribine tablets in patients with relapsing remitting multiple sclerosis: a pilot study
    van Pamelen, Jeske
    Rodriguez-Mogeda, Carla
    van Olst, Lynn
    van der Pol, Susanne M. A.
    Boon, Maarten L.
    de Beukelaar, Janet
    Gerlach, Oliver H. H.
    Budding, Andries E.
    Killestein, Joep
    de Vries, Helga E.
    Visser, Leo H.
    BIA study group
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [37] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Adeniji, Abidemi K.
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1594 - 1604
  • [38] Five-year study of adherence to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results
    Ramo, C.
    Arroyo, E.
    Sanchez-Solino, O.
    JOURNAL OF NEUROLOGY, 2009, 256 : S125 - S125
  • [39] Year-by-year lymphopenia rates in patients with relapsing multiple sclerosis (RMS) treated with cladribine tablets 3.5mg/kg in CLARITY and re-treated in CLARITY Extension
    Cook, Stuart
    Comi, Giancarlo
    Giovannoni, Gavin
    Rieckmann, Peter
    Soelberg-Sorensen, Per
    Vermersch, Patrick
    Dangond, Fernando
    Hicking, Christine
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP11 - NP11
  • [40] Safety and tolerability of cladribine tablets added to IFN-beta therapy in patients with active relapsing multiple sclerosis: final results from the ONWARD study (amended protocol)
    Montalban, X.
    Cohen, B.
    Leist, T.
    Moses, H.
    Hicking, C.
    Dangond, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 409 - 410
12345